

FDA begins process that will end the use of bevacizumab (Avastin®) for metastatic breast cancer.

Printed from <https://www.cancerquest.org/newsroom/2010/12/fda-begins-process-will-end-use-bevacizumab-avastinr-metastatic-breast-cancer> on 12/15/2025



The Food and Drug Administration (FDA) has begun the process of withdrawing the approval of bevacizumab (Avastin®) for the treatment of breast cancer. The agency states that the benefits of Avastin® do not outweigh the risks for this cancer type.

Source

<https://www.ncbi.nlm.nih.gov/pubmed/23960813>

Learn More

[Targeted Therapy](#)